ID   MCF-7.5C
AC   CVCL_DC70
SY   MCF7:5C; MCF-7 clone 5C; 5C
DR   cancercelllines; CVCL_DC70
DR   Wikidata; Q54904329
RX   PubMed=9242427;
RX   PubMed=1301400;
RX   PubMed=16333030;
RX   PubMed=32453591;
CC   Population: Caucasian.
CC   Characteristics: Undergoes rapid and complete apoptosis in the presence of physiologic concentrations of 17-alpha-estradiol.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 13
//
RX   PubMed=9242427;
RA   Levenson A.S., Jordan V.C.;
RT   "MCF-7: the first hormone-responsive breast cancer cell line.";
RL   Cancer Res. 57:3071-3078(1997).
//
RX   PubMed=1301400; DOI=10.1016/0303-7207(92)90104-E;
RA   Jiang S.-Y., Wolf D.M., Yingling J.M., Chang C.-S., Jordan V.C.;
RT   "An estrogen receptor positive MCF-7 clone that is resistant to
RT   antiestrogens and estradiol.";
RL   Mol. Cell. Endocrinol. 90:77-86(1992).
//
RX   PubMed=16333030; DOI=10.1093/jnci/dji400;
RA   Lewis J.S., Meeke K., Osipo C., Ross E.A., Kidawi N., Li T.-Y., Bell E.,
RA   Chandel N.S., Jordan V.C.;
RT   "Intrinsic mechanism of estradiol-induced apoptosis in breast cancer
RT   cells resistant to estrogen deprivation.";
RL   J. Natl. Cancer Inst. 97:1746-1759(2005).
//
RX   PubMed=32453591; DOI=10.1021/acs.jmedchem.0c00456;
RA   Li Y.-F., Zhao J., Gutgesell L.M., Shen Z.-N., Ratia K., Dye K.,
RA   Dubrovskyi O., Zhao H.-P., Huang F., Tonetti D.A., Thatcher G.R.J.,
RA   Xiong R.;
RT   "Novel pyrrolopyridone bromodomain and extra-terminal motif (BET)
RT   inhibitors effective in endocrine-resistant ER+ breast cancer with
RT   acquired resistance to fulvestrant and palbociclib.";
RL   J. Med. Chem. 63:7186-7210(2020).
//